AstraZeneca on Monday touted the competitive potential of its weight management pipeline at The Obesity Society’s ObesityWeek 2024 meeting in San Antonio, Texas, revealing early data for its oral GLP-1, a selective amylin agonist and a fixed-dose combination therapy.
Leading the pharma’s weight loss program is AZD5004, a small molecule oral GLP-1 receptor blocker licensed in November 2023 from Shanghai-based biotech Eccogene. At ObesityWeek, AstraZeneca unveiled early data for AZD5004, touting a clean safety profile for the investigational pill.
AZD5004 in healthy participants did not result in serious adverse events, while gastrointestinal toxicities became increasingly common at doses at or above 50 mg. In type 2 diabetes patients on metformin treatment, AZD5004 led to more side effects than placebo, particularly gastrointestinal in nature—though none of the side effects were serious…